ABSTRACT
Purpose@#A relatively low response to chemotherapy has been reported for hormone receptor (HR)-positive breast cancer. In this study, we investigated the role of tryptophanyl-transfer RNA synthetase (WARS) in the chemotherapeutic response of HR-positive breast cancer. @*Methods@#Pre-chemotherapeutic needle biopsy samples of 45 HR-positive breast cancer patients undergoing the same chemotherapeutic regimen were subjected to immunohistochemistry. To investigate the biological functions of WARS in HR-positive breast cancer, we conducted cell viability assay, flow cytometry analysis, caspase activity assay, Quantitative real-time polymerase chain reaction, and western blotting using WARS gene-modulated HR-positive breast cancer cells (T47D, ZR-75-1, and MCF7). @*Results@#WARS overexpression in HR-positive breast cancer patients showed a significant correlation with favorable chemotherapy response. Downregulation of WARS increased cell viability following docetaxel treatment in tumor cell lines. On the other hand, WARS overexpression sensitized the therapeutic response to docetaxel. Additionally, downregulation of WARS caused a decrease in the number of apoptotic cell populations by docetaxel. Poly (ADP-ribose) polymerase cleavage and caspase 3/7 activity were increased in docetaxel-treated tumor cells with WARS overexpression. @*Conclusion@#Our results suggest that WARS might be a potential predictor for chemotherapy response in patients with HR-positive breast cancer as well as a novel molecular target to improve chemosensitivity.
ABSTRACT
Purpose@#A relatively low response to chemotherapy has been reported for hormone receptor (HR)-positive breast cancer. In this study, we investigated the role of tryptophanyl-transfer RNA synthetase (WARS) in the chemotherapeutic response of HR-positive breast cancer. @*Methods@#Pre-chemotherapeutic needle biopsy samples of 45 HR-positive breast cancer patients undergoing the same chemotherapeutic regimen were subjected to immunohistochemistry. To investigate the biological functions of WARS in HR-positive breast cancer, we conducted cell viability assay, flow cytometry analysis, caspase activity assay, Quantitative real-time polymerase chain reaction, and western blotting using WARS gene-modulated HR-positive breast cancer cells (T47D, ZR-75-1, and MCF7). @*Results@#WARS overexpression in HR-positive breast cancer patients showed a significant correlation with favorable chemotherapy response. Downregulation of WARS increased cell viability following docetaxel treatment in tumor cell lines. On the other hand, WARS overexpression sensitized the therapeutic response to docetaxel. Additionally, downregulation of WARS caused a decrease in the number of apoptotic cell populations by docetaxel. Poly (ADP-ribose) polymerase cleavage and caspase 3/7 activity were increased in docetaxel-treated tumor cells with WARS overexpression. @*Conclusion@#Our results suggest that WARS might be a potential predictor for chemotherapy response in patients with HR-positive breast cancer as well as a novel molecular target to improve chemosensitivity.
ABSTRACT
Gestational trophoblastic tumors including choriocarcinoma bave become one of the most curable human malignancies with an overall cure rate exceeding 90%. Although systemic chemotherapy is the initial treatment for chorio- carcinoma, some patients with chemotherapy-resistant choriocarcinorna can be treated by integration of cbemotherapy, surgery and radio- therapy. We report two cases of persistent localized choriocarcinoma which was treated by surgical intervention.
Subject(s)
Female , Humans , Pregnancy , Choriocarcinoma , Drug Therapy , Neoplasm Metastasis , Trophoblastic NeoplasmsABSTRACT
Despite widespread clinical acceptance and use of Papanicolaou (Pap) test, cervical cancer remains a disease of prime importance in Korea. The purpose of this study was to investigate the supportive role of cervicography in screening test for uterine cervical cancer. Pap test and cervigram data were obtained from 220 patients who visited the cancer detection center of the department of obstetrics and gynecology, Yonsei University College of Medicine from Jul.1997 to Feb.1998. Histologic specimens were obtained from patients in whom abnormalities were detected by either Pap test or cervigram. Histologic confirmation were taken either by colposcopically directed biopsy (CDB) or large loop excision of the transformation zone (LLETZ). The results were as follows: 1. Pap test (209 cases) outcomes were WNL in 119 cases (57.0%), ASCUS in 12 cases (5.7%), LSIL in 11 cases (5.3%), HSIL in 48 cases (22.9%), and SCC in 19 cases (9.1%). 2. Cervicography (209 cases) outcomes were negative cervigram (N1, N2) in 53 cases (25.7%), benign atypia (B1, B2) in 61 cases (29.6%), suspicious atypia (S1, S2) in 59 cases (28.6%), and positive (PL, PH, PC) in 33 cases (16.1%). Technically defect (TD) in 3 cases were exclusive in analysis. 3. When cervicography and Pap test were used together, the sensi- tivity (P<0.01) and negative predictive value (P<0.01) were increased than for cervicography alone. 4. When cervicography and Pap test were used together, the sensitivity (P<0.01) and negative predictive value (P<0.05) were increased than for Pap test alone. Our study revealed that cervicography combined with Pap test improved the sensitivity and negative predictive value (NPV) in the screening of uterine cervical cancer. In conclusion, cervicography may play a supportive role in the screening of uterine cervical cancer.
Subject(s)
Humans , Biopsy , Gynecology , Hydrogen-Ion Concentration , Korea , Mass Screening , Obstetrics , Uterine Cervical NeoplasmsABSTRACT
Despite widespread clinical acceptance and use of Papanicolaou (Pap) test, cervical cancer remains a disease of prime importance in Korea. The purpose of this study was to investigate the supportive role of cervicography in screening test for uterine cervical cancer. Pap test and cervigram data were obtained from 220 patients who visited the cancer detection center of the department of obstetrics and gynecology, Yonsei University College of Medicine from Jul.1997 to Feb.1998. Histologic specimens were obtained from patients in whom abnormalities were detected by either Pap test or cervigram. Histologic confirmation were taken either by colposcopically directed biopsy (CDB) or large loop excision of the transformation zone (LLETZ). The results were as follows: 1. Pap test (209 cases) outcomes were WNL in 119 cases (57.0%), ASCUS in 12 cases (5.7%), LSIL in 11 cases (5.3%), HSIL in 48 cases (22.9%), and SCC in 19 cases (9.1%). 2. Cervicography (209 cases) outcomes were negative cervigram (N1, N2) in 53 cases (25.7%), benign atypia (B1, B2) in 61 cases (29.6%), suspicious atypia (S1, S2) in 59 cases (28.6%), and positive (PL, PH, PC) in 33 cases (16.1%). Technically defect (TD) in 3 cases were exclusive in analysis. 3. When cervicography and Pap test were used together, the sensi- tivity (P<0.01) and negative predictive value (P<0.01) were increased than for cervicography alone. 4. When cervicography and Pap test were used together, the sensitivity (P<0.01) and negative predictive value (P<0.05) were increased than for Pap test alone. Our study revealed that cervicography combined with Pap test improved the sensitivity and negative predictive value (NPV) in the screening of uterine cervical cancer. In conclusion, cervicography may play a supportive role in the screening of uterine cervical cancer.